Quantcast
Channel: Hong Kong Headlines on One News Page
Viewing all 51750 articles
Browse latest View live

Weibo Corporation to Report Second Quarter 2018 Financial Results on August 8, 2018

0
0
Weibo Corporation to Report Second Quarter 2018 Financial Results on August 8, 2018 BEIJING, July 31, 2018 /PRNewswire/ -- Weibo Corporation (NASDAQ: WB), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the second quarter of 2018 before the market opens on Wednesday, August 8, 2018. Following the announcement, Weibo's management team will host a conference call from 7 AM - 8 AM Eastern Time on August 8, 2018 (or 7 PM - 8 PM Beijing Time on August 8, 2018) to present an overview of the Company's financial performance and business operations.

A live webcast of the call will be available through the Company's corporate website at http://ir.weibo.com. Dial-in to the conference call can be accessed as follows:

US Toll Free:

+1 866-519-4004

Hong Kong Toll Free: 

800-906-601

China:

400-620-8038

International:

+65 6713-5090

Passcode for all regions:

2574828

A replay of the conference call will be available from 10:00 AM Eastern Time on August 8, 2018 - 09:59 AM Eastern Time on August 16, 2018. The dial-in number is +61 2-8199-0299. The passcode for the replay is 2574828.

*About Weibo Corporation*

Weibo is a leading social media for people to create, share and discover content online. It combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Weibo has developed and is continuously refining its social interest graph recommendation engine, which enables its customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness.

*Safe Harbor Statement*

This press release contains forward-looking statements that relate to, among other things, Weibo's expected financial performance and strategic and operational plans (as described, without limitation, in the "Business Outlook" section and in quotations from management in this press release. Weibo may also make forward-looking statements in the Company's periodic reports to the U.S. Securities and Exchange Commission ("SEC"), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology, such as "will,""expects,""anticipates,""future,""intends,""plans,""believes,""confidence,""estimates" and similar statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, Weibo's limited operating history in certain new businesses; failure to grow active user base and the level of user engagement; the uncertain regulatory landscape in China; fluctuations in the Company's quarterly operating results; the Company's reliance on advertising and marketing sales for a majority of its revenues; failure to successfully develop, introduce, drive adoption of or monetize new features and products; failure to compete effectively for advertising and marketing spending; failure to successfully integrate acquired businesses; risks associated with the Company's investments, including equity pick-up and impairment; failure to compete successfully against new entrants and established industry competitors; changes in the macro-economic environment, including the depreciation of the Renminbi; and adverse changes in economic and political policies of the PRC government and its impact on the Chinese economy. Further information regarding these and other risks is included in Weibo's annual report on Form 20-Fs and other filings with the SEC. All information provided in this press release is current as of the date hereof, and Weibo assumes no obligation to update such information, except as required under applicable law.

*Contact:*

Investor Relations
Weibo Corporation
Phone: +8610 5898-3017
Email: ir@staff.weibo.com

View original content:http://www.prnewswire.com/news-releases/weibo-corporation-to-report-second-quarter-2018-financial-results-on-august-8-2018-300688973.html Reported by PR Newswire Asia 7 hours ago.

Hong Kong technology and software stocks clobbered as US equity market rout continues

0
0
Hong Kong stocks continued to slide on Tuesday, with technology and software shares taking a beating in the wake of a market tumult in the US that saw prices tumbling at companies including Twitter, Facebook, Netflix and Intel. The Hang Seng Index slipped 0.5 per cent, or 150.12 points, to 28,583.01, and the China Enterprises Index was down 0.2 per cent, or 21.59 points, to 11,024.73. Meanwhile, in mainland China, the Shanghai Composite Index rose 0.3 per cent, or 7.35 points, to 2,876.40,... Reported by S.China Morning Post 6 hours ago.

China’s Sinochem to float oil refining, storage unit in US$2 billion Hong Kong IPO

0
0
Sinochem Energy, China's largest commercial petroleum fuel storage company, aims to raise US$2 billion via an initial public offering in Hong Kong, according to a source close to the deal. It is the first IPO of a central government-administered oil refining and trading firm since China Petroleum & Chemical (Sinopec)'s simultaneous listing in New York, London and Hong Kong 18 years ago. The flotation comes as the unit’s parent, Sinochem Corporation, is close to merging with... Reported by S.China Morning Post 6 hours ago.

China Literature to Report 2018 First Half Financial Results on August 13, 2018

0
0
China Literature to Report 2018 First Half Financial Results on August 13, 2018 *-Earnings Conference Call to be Held on Monday, August 13, 2018
**at 8:00 pm (Hong Kong Time) / 8:00 am (Eastern Time)*

HONG KONG, July 31, 2018 /PRNewswire/ -- China Literature Limited ("China Literature" or "the Company", 0772.HK), a leading online literature platform in China, will announce its financial results for the first half of 2018 ended June 30, 2018 on *Monday, August 13, 2018*.

The earnings release will be available on China Literature's investor relations website at http://ir.yuewen.com.

China Literature's management team will host a conference call to present an overview of the Company's financial performance and business operations. A live webcast of the call can be accessed on the Company's investor relations website.

Details of the conference call and webcast are as follows:

Time:                               8:00 pm (Hong Kong Time) / 8:00 am (Eastern Time)
Language:                       English
Webcast:                         http://ir.yuewen.com/en/ir-calendar/webcasts-calls/1H2018
Dial-in Numbers:
                                        U.S. Toll Free: 1866 519 4004
                                        Hong Kong: +852 3018 6771
                                        Mainland China (Landline): 800 819 0121 
                                        Mainland China (Mobile): 400 620 8038
                                        U.K.: +44 20 3621 4779 
                                        International: +65 6713 5090
                                        Passcode: 3248058A replay of the conference call will be available from 11:00 pm (Hong Kong Time) on August 13, 2018 for 7 days.

                                        U.S. Toll Free: 1855 452 5696
                                        International: +61 2 8199 0299
                                        Passcode: 3248058

Archived webcast will be available at the same link above.

*Contact *

For investors / analysts:                                                
Maggie Zhou                                                                 
Tel: +8621 6187 0500 ext. 80605                                 
Email: IR@yuewen.com 

For media:
Vivian Wang
Tel: +852 2232 3978
Email: vwang@Christensenir.com                                                 View original content:http://www.prnewswire.com/news-releases/china-literature-to-report-2018-first-half-financial-results-on-august-13-2018-300689179.html

Related Links :

http://ir.yuewen.com Reported by PR Newswire Asia 6 hours ago.

China Tower’s retail shares only just sell out as biggest IPO of 2018 fails to woo the public

0
0
China Tower has only just managed to sell all the shares available to the public in its Hong Kong IPO, the biggest worldwide for almost four years, according to people familiar with the deal. The mobile phone tower operator, which is seeking to raise up to HK$68.1 billion(US$8.7 billion) through its stock market flotation, allocated 5 per cent of the offering to the Hong Kong public. The tranche, worth HK$3.4 billion – not a huge retail book for individual investors – was only just... Reported by S.China Morning Post 5 hours ago.

Orig3n and ZhongAn, China's Largest E-Insurer Announce Partnership on Health Tech

0
0
Orig3n and ZhongAn, China's Largest E-Insurer Announce Partnership on Health Tech BOSTON and SHANGHAI, July 31, 2018 /PRNewswire/ -- Orig3n, Inc., a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine, and ZhongAn Online P&C Insurance Co., Ltd. (6060.HK), the first and largest online-only insurance company in China, today announced a new partnership to bring health tech solutions to Chinese consumers. 

ZhongAn, which raised US$1.5 billion during its oversubscribed IPO on the Hong Kong stock exchange in late 2017, Asia's largest-ever fintech offering at that time, primarily offers insurance products and solutions in the context of five major ecosystems, namely lifestyle consumption, consumer finance, health, auto, and travel. The company will now supplement its insurance offerings with the introduction of healthcare solutions including a suite of DNA tests to their extensive customer base of nearly 500 million people, and to the China market as a whole. The product suite will be backed by Orig3n's extensive knowledge of genetic testing applications, being one of the leading US direct-to-consumer DNA test platforms.

"We are very excited to have ZhongAn as a strategic partner in China," said Robin Y. Smith, CEO of Orig3n. "With our strong knowledge base and IP and ZhongAn's brand awareness and extensive reach with consumers, we are confident that together we will make a significant impact in the PRC."

Liu Haijiao, President of Life Sciences at ZhongAn commented, "We had been looking to complement ZhongAn's product suite with health tech solutions to meet evolving consumer demands and identified Orig3n as the ideal partner due to its technology and industry-leading mobile platform. We look forward to partnering with Orig3n to provide innovative new products for our customers and the broader China market," said Liu.

The two companies also agree to establish a new laboratory in Shanghai, which focuses on the application and innovation of healthcare technologies. Locating the lab in Shanghai will also enable the companies to provide Chinese consumers with personalized, efficient and convenient healthcare solutions.

*About Orig3n, Inc.  *
Orig3n exists at the intersection of biological science and emerging technology on a mission to revolutionize the future of medicine. As part of its mission to democratize access to genetic information, Orig3n provides consumers direct, affordable access to information about their lifestyle-related genes, thereby empowering people to make educated, proactive and personalized lifestyle choices that may impact their well-being. Orig3n also invests in breakthrough cell therapy programs by utilizing cutting-edge cellular science to develop personalized therapies for repairing tissue damage and treating disease.  Since its inception in 2014, Orig3n has built the largest suite of direct-to-consumer genetic tests on the market, and the world's most comprehensive cell bank for commercial regenerative medicine applications.  The company recently announced a Series B financing and has raised $50MM in funding since its founding.  For more information, visit www.orig3n.com/our-mission/.

*About ZhongAn Online P&C Insurance Co., Ltd.*
ZhongAn Online P & C Insurance Co., Ltd. is an online-only InsureTech company in China. It started operations in October 2013 and has developed ecosystem-oriented insurance products and solutions through scenario-based settings to serve its customers. The company primarily offers products and solutions in the context of five major ecosystems, namely lifestyle consumption, consumer finance, health, auto, and travel. ZA Online was the largest insurer in China as measured by the number of insurance policies sold and policyholders and the insured served since its inception in October 2013 to 31 December 2016. In November 2016, ZA Online set up ZhongAn Technology, a wholly-owned subsidiary which focuses on the research and development of cutting-edge financial technologies to export technological capabilities to the industry. On 28 September 2017, ZA Online became the first Fintech company to be listed on the HKEX.

Contact: Rebecca Taylor
630-484-3904
rebecca.taylor@edelman.com

Photo - https://mma.prnewswire.com/media/724936/group_shot.jpg  
Photo - https://mma.prnewswire.com/media/724937/Orig3n_speaker.jpg

Related Links :

http://www.orig3n.com Reported by PR Newswire Asia 2 hours ago.

Mrunal Thakur talks about the experience of staying in Sonagachi, India's largest red-light area

0
0
Kumkum Bhagya fame Mrunal Thakur, is all set to make her Bollywood debut with Hrithik Roshan starrer 'Super 30'. She is currently gearing up for the special screening of her Indie film 'Love Sonia' at the prestigious Indian Film Festival of Melbourne. 

Love Sonia, that is based on child trafficking, reunited directed Tabrez Noorani (who is also the Indian producer of Slumdog Millionaire) with reel life Latika, Freida Pinto. Mrunal took the role of Sonia, a young girl from a small Indian village, after a year-long search of a good film that really connected to her.

Sonia’s life changes forever when her greedy father sells off Preeti, his younger daughter to a small pimp in order to save his farm, in the thought that she will find a living in Mumbai. In an attempt to save her sister, Sonia dives into the corrupt world herself, determined not to become one of the targets of the brutal sex trade network.

Mrunal said, “The film is about how Sonia courageously and smartly attempts to track down her sister. Her journey travels across India but also to Hong Kong and the US.”

Mrunal Thakur calls her co-stars, Demi Moore and Freida Pinto as wonderful women. She recollects, “Demi shared stories of working with an organization called Thorn (that works towards curbing circulation of child sexual abuse material and stands up to traffickers. I went to Sonagachi, the red light area in Kolkata, and lived there for a couple of days, studying the body language of the girls there. I also interacted with the organization called Apne Aap that helps such women and gets their children admitted into schools.”

The film has been shot in Jaipur, Mumbai, Hong Kong, and Los Angeles, and will be released in India this September. The film is based on an eye-opening story of global sex trafficking and has a strong ensemble cast comprising of Hollywood as well as Bollywood actors, including Freida Pinto, Manoj Bajpayee, Rajkummar Rao, Richa Chadha, Anupam Kher, Adil Hussain, Sai Tamhankar, Lion fame Sunny Parwar, Demi Moore, Mark Duplass and Riya Sisodiya.

Article Type: 
Report
Sections: 
Bollywood
Entertainment
Television
Authors: 
DNA Web Team
Agencies: 
DNA webdesk
Tags: 
Love Sonia
Mrunal Thakur
Kumkum Bhagya
Sonagachi
Tue, 31 Jul 2018-08:39pm
Date updated: 
Tuesday, 31 July 2018 - 9:13pm
Article Images: 
Instagram
Short URL: 
dnai.in/2
Embargo: 
Syndicate: 
Hide lead image: 
Page views: 
1
From Print Edition: 
Highlights:  Reported by DNA 1 hour ago.

Federvini, Unione Italiana Vini, FederDOC, and FIVI Vignaioli Indipendenti Forge Ahead to Form the Institutional Advisory Board for Vinitaly International Academy

0
0
Vinitaly International Academy (VIA) welcomes the main Italian associations in the wine industry in support of its educational project. Following the appointment of Italian academic Prof. Attilio Scienza as its Chief Scientist, VIA starts a productive dialogue with Federvini, Unione Italiana Vini (UIV), FederDOC, and FIVI Vignaioli Indipendenti on the trajectories of Italian wine education abroad.

VERONA, Italy (PRWEB) July 31, 2018

On Friday July 13th, 2018, VIA Founder Stevie Kim and VIA Chief Scientist Attilio Scienza met the representatives of the four major institutions in the Italian wine sector, that will form the new VIA’s Institutional Advisory Board. At wine2digital in Verona, Kim and Scienza discussed VIA’s enlarged and reformatted project with FederDOC President Riccardo Ricci Curbastro and Director Cristiana Tirabovi, Federvini Director Ottavio Cagiano, UIV Communications Director Giulio Somma, and FIVI President Matilde Poggi. The associations endorsed VIA’s new directions and commitment to build the international gold standard for Italian wine education as well as the so-called VIA Ecosystem, the educational and administrative infrastructure that will engage not only wineries and professionals from all over the world, but also the Italian wine world at large, with local bodies like consortiums. VIA’s Institutional Advisory Board members will act as the institutional guarantors of the project and will help enhance the connections between the sector in Italy and international trade professionals that come to Italy to learn more about its wines.

In the Italian wine sector, the four institutions that will collaborate with VIA oversee the interests of wineries and of wine production in Italy. FederDOC (Confederazione Nazionale Consorzi Volontari per la tutela delle denominazioni dei vini italiani) is the national association that groups together wine consortiums and that looks after the certification of territory-specific appellations. Federvini is the industrial association bringing under its tutelage larger producers of wine, spirits, vinegar, and other wine-related products. UIV (Unione Italiana Vini) is a category-specific association of winery owners instituted in 1895 that combines all the various companies pertaining to the sector (individual wine growers, more structured wineries, wine cooperatives and industries). FIVI (Federazione Italiana Vignaioli Indipendenti) is the association that lobbies at national and European level to safeguard independent wine growers.

All representatives of the associations fully supported VIA’s educational objectives and gave their availability and commitment to work together in the name of Italian wine. FIVI President Matilde Poggi comments: “We are very proud, and I am very proud to have been invited here to participate as part of the Institutional Advisory Board. I believe that Vinitaly International Academy is doing exactly what was really needed for Italian wine and no one else has achieved this thus far.” Federvini Director Ottavio Cagiano acknowledges VIA’s efforts in its educational enterprise: “At the forefront, Vinitaly International Academy has done enormous work in this area. We are very interested and in need of this collaboration with VIA as we look to improve on the way we develop future initiatives.” On the collaboration with VIA, FederDOC president Curbastro adds: “We always talk about Italian wine as one of the great masterpieces of the world, but it’s true that we need more and more passionate ambassadors and people that can better develop and interpret the knowledge about what we do, the passion of the producers, the different landscapes and the different territories we represent. For this reason, the cooperation between FederDOC and Vinitaly Academy is something that I see as one of the key points for the future of Italian wine.” UIV’s Communications Director Giulio Somma looks forward to working with VIA, stressing that the collaboration is “the first organized experience of high-level education on Italian wine, an essential tool to promote the diversity of Italian wine and its richness in production. UIV is willing to contribute as a system of wine companies and avail of the benefits of this collaboration and educational activities for their members and, more generally, for the Italian wine companies, thus starting a dialogue that will be very important, surely, for the whole wine sector.”

The next VIA Certification Course will take place in Hong Kong from November 4th to 8th, prior to the Hong Kong International Wine & Spirits Fair. It will be taught by new Faculty members Sarah Heller MW and Henry Davar. The application form and additional information are available here: https://www.vinitalyinternational.com/?page_id=1785.

About
The grand Vinitaly 2019 will be held from April 7th to the 10th. Every year, Vinitaly counts more than 4,000 exhibitors on a 100,000+ square meter area and 130,000 visitors from over 140 different countries with more than 30,000 top international buyers. The premier event to Vinitaly, OperaWine (https://www.vinitalyinternational.com/?page_id=646) “Finest Italian Wines: 100 Great Producers,” which will be held on the 6th of April, one day prior to Vinitaly will unite international wine professionals in the heart of Verona, offering them the unique opportunity to discover and taste the wines of the 100 Best Italian Producers, as selected by Wine Spectator. Since 1998 Vinitaly International travels to several countries such as Russia, China, USA and Hong Kong thanks to its strategic arm abroad, Vinitaly International. In February 2014 Vinitaly International launched an educational project, the Vinitaly International Academy (VIA) with the aim of divulging and broadcasting the excellence and diversity of Italian wine around the globe. VIA this year launched the seventh edition of its Certification Course and today counts 151 Italian Wine Ambassadors and 11 Italian Wine Experts. Reported by PRWeb 2 hours ago.

Turing probably can’t build its crazy new smartphone, but I’d love to see it try

0
0
Turing probably can’t build its crazy new smartphone, but I’d love to see it try Remember Turing Robotic Industries, the company that promised to build a smartphone with end-to-end encryption and a durable ‘Liquidmorphium’ body? That plan didn’t quite pan out, but the company is back with a new name – and a new device in the works. The Hong Kong-headquartered firm is now called Turing Space Industries (TSI), and it’s just unveiled the HubblePhone, a wildly inventive mobile device that’s slated to ship in 2020. The company describes it as a 5G-capable Android device with separate AMOLED displays on two ‘decks’ that swivel around to allow for various shooting and viewing modes, a 60-megapixel primary camera…

This story continues at The Next Web Reported by The Next Web 11 hours ago.

What Hong Kong exchange has done to attract IPOs of new economy firms

0
0
In April, bourse operator Hong Kong Exchanges and Clearing (HKEX) introduced its biggest listing reform for 25 years with the aim of turning the city’s stock exchange as a listing hub for technology and biotechnology companies which now are mainly listed in the US. But the reforms have yet to work their magic for the exchange as only two companies have successfully listed so far. Biotech firm Ascletis Pharma made its debut on August 1 and smartphone maker Xiaomi in July. What types of... Reported by S.China Morning Post 11 hours ago.

Explainer: Here’s what Hong Kong exchange has done to attract IPOs of new economy firms

0
0
In April, bourse operator Hong Kong Exchanges and Clearing (HKEX) introduced its biggest listing reform for 25 years with the aim of turning the city’s stock exchange as a listing hub for technology and biotechnology companies which now are mainly listed in the US. But the reforms have yet to work their magic for the exchange as only two companies have successfully listed so far. Biotech firm Ascletis Pharma made its debut on August 1 and smartphone maker Xiaomi in July. What types of... Reported by S.China Morning Post 11 hours ago.

Quipper Represented Indonesia at the EdTech Asia Summit 2018 Held in Hong Kong

0
0
Quipper Represented Indonesia at the EdTech Asia Summit 2018 Held in Hong Kong JAKARTA, Indonesia, Aug. 1, 2018 /PRNewswire/ -- EdTech Asia Summit, the biggest education technology industry event, was held in Hong Kong from 26 - 27 July 2018. With the theme of "Learning and Workshop Innovation and Insights", the event was attended by hundreds of education technology companies, inventors, entrepreneurs and education organizations from all over Asia. Quipper, in this occasion, received an opportunity to represent Indonesia in a panel discussion session.Takuya Homma, Country Manager Quipper Indonesia in the panel discussion

The panel discussion topics ranged from education technology landscape in Asia, the use of Artificial Intelligence, the role of teachers and many others. Takuya Homma, the Country Manager of Quipper Indonesia, spoke alongside other players in education technology sectors namely ALSET (National University of Singapore), Topica (Vietnam), Edukasyon (The Philippines) and Jaipuna (New Zealand). The topic discussed in the conference was *ASEAN's Emerging Tiger Markets: Opportunities and Challenges. *  

As some of the strongest EdTech powerhouses with strong business foundations, Quipper and Topica were asked to share challenges and opportunities in building EdTech businesses with such explosive growth in the region.

Takuya said, "Quipper, as one of the biggest EdTech players in the region, feels a responsibility to set the right and clear agenda for future education dialogues, so that the education industry in Southeast Asia will continue to grow fast, as education is a very important component for the future prosperity of the region."

Other Indonesian representatives participating in Edtech Asia Summit 2018 were Zenius and Solve Education! Sabda, the founder of Zenius, said, "Indonesia is one of the fastest growing EdTech markets in the world, and there is a huge potential and room for improvement. We are dedicated to developing a healthy education ecosystem with various players in the nation, and grow this important industry together with them."

"Efficacy and effectiveness are very important in education. I'm glad to see some players are talking about this, and we want to bring high quality education to Indonesia," added Talitha from Solve Education!

Quipper, being the global leading EdTech company that is committed to providing access to high quality education for Indonesia, expects that all elements of society will give their contribution to deliver quality education content in Indonesia. 

*About Quipper*

Quipper is a global leading education technology company that strives to bring the best education to every corner of the world. We believe every child deserves an opportunity to learn - an opportunity to create the future they aspire to. At Quipper, we harness technology to achieve just this.

Quipper services empower educators and learners alike by breaking down barriers in learning to help learners realize their full potential through our products: Quipper Video, Quipper School and Quipper Campus. Currently Quipper services have been used by more than 5 million students and more than 350,000 teachers and operated in five countries: United Kingdom, Japan, Philippines, Mexico and Indonesia.

For more info, please visit www.quipper.com

*Media Contact
**Quipper Indonesia
*Ike Yuningsih
Public Relations
ike.yuningsih@quipper.com
+62-1-2953-3315

Photo - https://photos.prnasia.com/prnh/20180801/2201340-1 Reported by PR Newswire Asia 11 hours ago.

WorldSkills Hong Kong 2018: Inspiring Skills Excellence

0
0
[Sponsored Article] Last week saw the successful completion of the months-long WorldSkills Hong Kong Competition 2018, in which top winners of 25 trades were selected. Hong Kong representatives will be chosen to take part in the WorldSkills Competition, hailed as the Skills Olympics, to be held in Kazan, Russia, next year. David Hoey, Chief Executive Officer of WorldSkills International with a vision to improve the world with the power of skills, was the guest of honour at the prize... Reported by S.China Morning Post 11 hours ago.

Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept

0
0
DGAP-News: Apogenix AG / Key word(s): Patent

01.08.2018 / 09:00
The issuer is solely responsible for the content of this announcement.
--------------------

Press Release

*Apogenix Strengthens Patent Position for Lead Drug Candidate Asunercept*

*Heidelberg, Germany, August 1, 2018 *- Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it was granted two key patents for lead immuno-oncology candidate asunercept in multiple territories.

A composition of matter patent protecting the product asunercept and its manufacturing process was already granted in 2016 by the U.S. Patent and Trademark Office. Apogenix has now received the corresponding composition of matter patents in Europe, Japan, Australia, and Russia. The patents are valid through 2033 in these territories.

The company was further granted a method of use patent covering the use of CD95 ligand inhibitors, such as asunercept, to treat patients with low to intermediate-1 risk myelodysplastic syndromes (MDS) in the United States, China, Japan, Australia, and Russia at least until 2033. The corresponding European patent was already granted in 2016. This is the second method of use patent that Apogenix has received for its lead drug candidate asunercept. The company already holds patents covering the medical use of CD95 ligand inhibitors for the treatment of glioblastoma in key territories such as Europe, the United States, Canada, and Japan. These patents are valid at least until 2027.

"Apogenix has a strong patent portfolio protecting its immuno-oncology projects in all leading pharmaceutical markets," said Thomas Hoeger, Ph.D., CEO of Apogenix. "These new patents expand the IP protection for asunercept even further and are critical in harnessing the medical and economic potential of this innovative drug candidate. We are currently preparing additional clinical trials with asunercept in both glioblastoma and MDS, so patients can benefit from this new therapeutic approach as soon as possible."

*About Asunercept*
Apogenix' lead immuno-oncology candidate asunercept is a fully human fusion protein that consists of the extracellular domain of the CD95 receptor and the Fc domain of an IgG1 antibody. It is being developed for the treatment of solid tumors and malignant hematological diseases. Asunercept was granted orphan drug designation for the treatment of glioblastoma and myelodysplastic syndromes (MDS) in both the EU and the US. In 2017, asunercept received PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of glioblastoma.

*About Apogenix*
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The Heidelberg, Germany-based company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the immune response against tumors. Checkpoint inhibitor asunercept, the company's lead immuno-oncology candidate, is in late-stage clinical development. Based on its proprietary technology platform for the construction of novel hexavalent TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, 4-1BB, and OX40 receptor agonists for cancer immunotherapy.

In 2015, Apogenix entered into an exclusive licensing agreement with CANbridge Life Sciences for the development and commercialization of asunercept for the treatment of glioblastoma in China, Macao, Hong Kong, and Taiwan. CANbridge has received approval by the China Food and Drug Administration for a pivotal phase II/III trial with asunercept (CAN008) in glioblastoma in China. The HERA-TRAIL receptor agonist program was partnered with AbbVie in 2014. In 2017, AbbVie initiated a phase I trial with this HERA-TRAIL receptor agonist (ABBV-621) in patients suffering from solid tumors, non-Hodgkins's lymphoma, or acute myeloid leukemia.

*Contact *
Thomas Höger, Ph.D., CEO
Apogenix AG
Phone: +49 6221 58608-0
E-Mail: contact@apogenix.com
Web: www.apogenix.com

*Media Contact *
Katja Arnold / Andreas Jungfer
MC Services AG
Phone: +49 89 210228-0
E-Mail: apogenix@mc-services.eu
--------------------

01.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de -------------------- Reported by EQS Group 11 hours ago.

China Unicom Voted "Asia's No. 1 Most Honored Telecom Company" for Third Consecutive Year

0
0
China Unicom Voted Asia's No. 1 Most Honored Telecom Company for Third Consecutive Year HONG KONG, Aug. 1, 2018 /PRNewswire/ -- *China Unicom (Hong Kong) Limited ("China Unicom" or "the Company") (HKEx: 0762; NYSE: CHU)* was voted three years in a row by portfolio managers and analysts as "Asia's No.1 Most Honored Telecom Company" in "2018 All-Asia Executive Team" ranking organised by Institutional Investor, a distinguished media with highly-respected proprietary benchmark research and rankings related to investment community.

The excellent recognitions mark the endorsement by professional investors and investment analysts of China Unicom's continuous enhancement in strategy execution and leading performance in corporate governance in Asia, especially its proactive implementation of the mixed-ownership reform and deepened implementation of "Focus, Innovation & Cooperation" Strategy to enhance corporate vibrancy and operating efficiency. China Unicom would like to sincerely thank its investors and the investment community for their kind support and the great vote of confidence.

Institutional Investor's "2018 All-Asia Executive Team" ranking reflected the opinions from more than 4,500 investment professionals at 1,270 financial institutions globally. The participating portfolio managers collectively manage an estimated US$1.6 trillion in Asia (ex-Japan) equities. Institutional Investor's confidential and unprompted voting gathers data from investors and analysts to determine rankings in Most Honored Companies among the Asian (ex-Japan) companies they cover, and to evaluate these businesses on selected corporate governance attributes. In 2018, 2,368 companies across 18 sectors were nominated in the ranking.China Unicom Voted “Asia’s No. 1 Most Honored Telecom Company” for Third Consecutive Year

Photo - https://photos.prnasia.com/prnh/20180801/2201260-1 Reported by PR Newswire Asia 11 hours ago.

Interim Results for 2018 Continues to Record a Significant Growth, Ausnutria Dairy Announces the Positive Profit Alert for Eight Consecutive Times

0
0
Continuous Increase in the Sales of the Own-branded Milk Formula Products; Gradually Enhances Operation Efficiency

HONG KONG, Aug 1, 2018 - (ACN Newswire) - Ausnutria Dairy Corporation Ltd ("Ausnutria" or the "Company", together with its subsidiaries, the "Group"; stock code: 1717.HK), a company engages in the research and development, production and distribution of all dairy products (including infant formula) and nutrition products with production facilities principally based in the Netherlands, Australia, New Zealand and the PRC, is pleased to announce that it is anticipated that the Group will record a profit attributable to the Shareholders (excluding the other income described below) of approximately RMB270.0 million for the six months ended 30 June 2018 (the "2018 Interim Period"), representing an increase of approximately RMB116.7 million or approximately 76.1% when compared with RMB153.3 million for the corresponding period of last year. The sales of the Group for the 2018 Interim Period is anticipated to increase by approximately 51.6% to approximately RMB2.58 billion, among which the sales of the Group's own-branded cow and goat milk formula products are anticipated to increase by approximately 80.5% and approximately 67.7% to approximately RMB1.17 billion and approximately RMB0.91 billion respectively, when compared with the 2017 Interim Period.

During the 2018 Interim Period, the Group recorded certain other income attributable to the gain on fair value changes of derivative financial instruments arising from the contingent consideration as a result of the Group's acquisition of the remaining 15% equity interest in a subsidiary; and a one-off gain arising from the re-measurement of the previously held interest in a joint venture as a result of the acquisition of its remaining 50% equity interest in the joint venture, of a total of approximately RMB61.8 million. Including the aforesaid other income, the reported profit attributable to Shareholders is anticipated to increase to approximately RMB331.8 million. The Group has continuously announced the positive alert for eight times from 2016 to the 2018 Interim Period.

The continuous improvement in the Group's financial performance was mainly attributable to the continuous increase in the sales of the Group's own-branded cow and goat milk formula products. Such increase was mainly contributed by the growing market recognition of the Group's own-branded formula milk products as a result of its persistent effort in building distribution channels and delivering quality consumer service; the rising worldwide awareness for the Group's own-branded goat milk formula products Kabrita for its quality and high nutrition value; the increase in production capacity following the acquisition of a factory in Australia and the commencement of production of two new factories in the Netherlands; and the progressive enhancement of the Group's management and operation efficiency.

Mr. Yan Weibin, Chairman of the Group, said "Ausnutria gradually implements its global strategy from upstream to the sales market. It has formed global expansion of a full industrial chain from formula milk powder to nutritional products, and has become an international company with a sales service network in China, North America, Europe, Russia and the Middle East. As to the core business, five factories in the Netherlands, two companies in Australia, and one factory in New Zealand have been reformed or completed and commenced production. The first factory in Changsha, the PRC, is in operation. Smart Factory in Changsha will be completed soon, and global 'Golden Milk Zone' layout is basically completed. As to the global business development, the Group has completed the acquisition of remaining 15% equity interest in HNC Group, and remaining 50% equity interest in Ozfarm Australia which has the number one maternal women's milk powder brand in Australia. Moreover, the Group will strategically introduce CITIC Agri Fund Management Co., Ltd. After CITIC Agri Fund becomes the single largest shareholder of the Group, this will broaden our shareholding structure, optimize the Group's asset and liability structure and enhance international competitiveness. In addition, the senior management increased stake in June this year fully demonstrates the core management's confidence in business performance and prospects of Ausnutria. In the future, the Group will follow the direction of nutrition and comprehensive health, seize the opportunities both in the PRC and overseas market, and enhance its sustainability, heading towards the 'Golden Decade' of Ausnutria."

About Ausnutria Dairy Corporation Ltd.
Ausnutria Dairy Corporation Ltd is a leading infant milk formula company with production facilities principally based in the Netherlands, Australia, New Zealand, and the PRC The Company is engaged in the worldwide production, research, and sales of infant formula, adult milk and other dairy and nutrition products. It owns several famous infant formula and milk powder brands, including Kabrita, Allnutria and Hyproca. Ausnutria's factories in the PRC were among that first batch of factories that had been granted with the National Infant Formula Enterprise Production Permit. The factory in the Netherlands is also one of the first infant milk formula manufacturers to obtain import licenses for overseas products under the new policy in the PRC.Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com Reported by ACN Newswire 6 hours ago.

Hong Kong SAR Retail Sales down to 12% in June from previous 12.9%

0
0
Reported by FXstreet.com 10 hours ago.

Ascletis Successfully Listed on the Main Board of HKEX

0
0
HONG KONG, Aug 1, 2018 - (ACN Newswire) - Recently, following the official implementation of the revised listing rules by the Hong Kong Stock Exchange (HKEX), the Hong Kong capital market has been opened up further, welcoming listing applications from several biotechnology companies. In particular, Ascletis Pharma Inc., the first biotechnology company successfully lodging its listing application after the overhaul of the listing rules, was listed on the main board of the HKEX yesterday, running ahead of its industrial peers.

As the market benchmark, Ascletis come to front for its listing
Several celebrities such as Charles Li, Chief Executive of HKEX; Xie Shuang Cheng, Deputy Mayor of Hangzhou Municipal People's Government; Song Rui Lin, Executive President of PhiRDA, and Stephen Phillips, Director-General of Investment Promotion of the Government of the Hong Kong Special Administrative Region all attended the listing ceremony of Ascletis to share the joy together.

It was learned that Ascletis has rapidly become a fully integrated anti-viral platform focused on developing, manufacturing and commercializing innovative, best-in-class drugs against HCV, HIV and HBV. Jinzi J. Wu, Ph.D., The founder of Ascletis said in the listing ceremony that over the past five years, Ascletis have stayed true to its original commitment and overcome many obstacles. It has already become the most high-profile new force in China's biotechnology industry by succeeding in building a complete value chain covering new drug development and commercialization for three areas, namely anti-viral, cancer and fatty liver disease, and launching the first domestically developed drug.

As the first listed biotechnology company after the listing rules overhaul, Ascletis has drawn wide market attention and gained positive response since the announcement of its global offering, owing to its unparalleled capabilities. According to publicly available information, HK$2,976.0 million was raised in this offering with an offer price of HK$14.00 per share. The Hong Kong public offering was significantly over-subscribed, while the international placing was over-subscribed as well.

Achieve remarkable achievements
Ascletis originates from a Latin word Asclepius, which refers to the god of medicine in ancient Greek mythology. Ascletis is sure worth this title.

According to Xinhua News, the launching conference for Ganovo (Danoprevir), the first direct-acting anti-viral agent (DAA) developed domestically in China, was held at the China National Convention Center recently. The launching of Ganovo has helped breaking the monopoly of Chinese HCV field by the international pharmaceutical giants. Bringing hope for cure for HCV patients in China

Ascletis announced that Ganovo phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association. As the first DAAdeveloped and launched successfully by a domestic company, the award further reinforces the medical community's confidence in Ganovo's excellent efficacy, better safety and tolerability, strong commitment to high quality drugs, and service to Chinese patients delivered by Ascletis as a local innovative biotech company.

What's more, Ascletis announced it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir new drug application (NDA). The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.

Jinzi J. Wu, Ph.D. said that Ascletis was successfully listed on HKEX in the morning and the NDA for all-oral HCV regimen was accepted by CFDA in the afternoon, these two significant accomplishments on the same day reflect Ascletis' unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill Ascletis commitment to the investors.

The successfully listed of Ascletis has injected new impetus to the Hong Kong capital market and attracted more biotechnology companies to seek a listing in Hong Kong.Copyright 2018 ACN Newswire. All rights reserved. www.acnnewswire.com Reported by ACN Newswire 5 hours ago.

CRYPTO.com Welcomes Litecoin to the MCO Cryptocurrency Platform

0
0
CRYPTO.com Welcomes Litecoin to the MCO Cryptocurrency Platform HONG KONG, Aug. 1, 2018 /PRNewswire/ --

LTC - first coin to be listed since the MCO Wallet App debut 

CRYPTO.com, the pioneering payments and cryptocurrency platform formerly known as Monaco, announced today that Litecoin (LTC) has been added to its MCO Wallet App, joining the four original cryptocurrencies on the platform - bitcoin (BTC), ether (ETH), Binance Coin (BNB), and CRYPTO.com's MCO. All can be purchased, exchanged, and sent securely within the app.

The debut of Litecoin marks the first cryptocurrency addition to the MCO platform since the MCO Wallet App launch. This addition further expands users' options for purchasing and trading cryptocurrency, and lays the groundwork for the launch of the MCO Visa Card.

*Kris Marszalek, Co-Founder and CEO of CRYPTO.com,* said: "By listing Litecoin on the MCO Wallet App, we are deepening both the functionality of the app for users and transforming into a go-to, intuitive cryptocurrency exchange platform. We look forward to continually and regularly expanding the variety of cryptocurrencies available to our platform users. Our support of Litecoin marks an essential step in this process as we strive to broaden the audience of cryptocurrency spenders and investors."

*Charlie Lee, Creator of Litecoin,* said: "Litecoin Foundation and CRYPTO.com share a common vision of accelerating the development and adoption of cryptocurrency. As Litecoin moves towards widespread acceptance as currency for a growing number of merchants, I'm excited to see Litecoin support added to the MCO Wallet App and the MCO Visa Card. We look forward to advancing the mission to expand cryptocurrency use together with CRYPTO.com by helping more users buy and spend Litecoins in their day-to-day lives."

By adding Litecoin to the MCO platform, CRYPTO.com is enabling MCO users to spend LTC, among other cryptocurrencies, with the MCO Visa Card once it becomes available in their market. Using the MCO Wallet App, users can buy, exchange, sell, and track their cryptocurrencies.

CRYPTO.com carefully reviews and evaluates cryptocurrencies on an ongoing basis for inclusion on the MCO Wallet app. This listing brings the total listed cryptocurrencies supported by MCO to five and supports the broader mission of CRYPTO.com to accelerate the world's adoption of cryptocurrency.

*About CRYPTO.com * 

CRYPTO.com, the pioneering payments and cryptocurrency platform, formerly known as Monaco, seeks to accelerate the world's transition to cryptocurrency. Its MCO branded consumer financial services, including the MCO Visa Card, MCO Wallet App, and MCO Token embrace a vision of Cryptocurrency in Every Wallet™. CRYPTO.com is headquartered in Hong Kong. For more information, please visit: http://www.crypto.com. Reported by PR Newswire Asia 9 hours ago.

Hong Kong stocks slip on renewed trade war fears, weaker China manufacturing data

0
0
Hong Kong stocks declined for a third day on Wednesday on the back of renewed trade war fears, weaker China manufacturing data and the country’s reiterated determination to curb home prices at a top leadership meeting. The Hang Seng Index fell 0.9 per cent, or 242.27 points, to 28,340.74. The Hang Seng China Enterprises Index dropped 0.5 per cent, or 51.69 points, to 10,973.04. In mainland China, the Shanghai Composite Index slid 1.8 per cent to 2,824.53. “People are turning... Reported by S.China Morning Post 8 hours ago.
Viewing all 51750 articles
Browse latest View live




Latest Images